Table 4.
Modeled difference in change from baseline for the respective endpoints comparing patients receiving hydromethylthionine 8 mg/day and 200 mg/day on primary and secondary outcomes. (UPDRS, although a safety outcome, is also included.)
| Decline±SEM for LMTM 8 mg/day group (n = 110) | Difference±SEM from LMTM 8 mg/day for 200 mg/day (n = 104) | CI | p | |
| ACE-R | –9.98±1.39 | –0.49±2.10 | –4.64, 3.66 | 0.8170 |
| FAQ | 5.51±0.55 | –0.39±0.84 | –2.05, 1.26 | 0.6410 |
| WBV (cm3) | –21.64±1.56 | –1.35±2.32 | –5.94, 3.23 | 0.5614 |
| MMSE | –3.41±0.53 | –0.12±0.80 | –1.69, 1.42 | 0.8836 |
| CGIC | –1.05±0.11 | –0.04±0.16 | –0.35, 0.28 | 0.8252 |
| FRS | –0.1240±0.0136 | 0.0075±0.0206 | –0.0332, 0.0482 | 0.7176 |
| ACE-III | –10.70±1.55 | 0.44±2.27 | –4.05, 4.93 | 0.8469 |
| UPDRS – part III | 3.90±1.06 | –1.40±1.61 | –4.59, 1.78 | 0.3850 |